A UK biomaterials technology company, BioInteractions, has launched a new medical devices coating technology, TridAnt, which represents a paradigm shift in the prevention of infection and protection against a wide range of pathogens.

Incorporating passive and active components to create an effective, non-leaching, durable and practical antimicrobial coating for medical implants and devices, TriAnt, focuses on developing the best bioengineering technique to bond the antimicrobial coating securely to the material of the different medical devices for their lifecycle.

“BioInteractions has launched a new medical devices coating technology.“

The innovative antimicrobial technology is safe to use in every environment, including implants inside the human body. Furthermore, it’s the first of its kind to exterminate non-enveloped and enveloped viruses and gram-positive and gram-negative bacteria to prevent the formation of biofilms for extended periods of up to 12 months without any apparent decrease in efficacy.

The Commercial Director for BioInteractions, Arjun Luthra, stated: “Strict hygiene regimes and existing disinfectants have limited efficacy in reducing the risk of infection for prolonged periods of time. Our TridAnt solution offers a new way to combat infections more effectively, efficiently and for longer. Based on over three decades of dedicated research and trials, TridAnt is fully compliant with current medical device regulations, has been independently tested to international standards (ISO, EN, PAS) and proven to provide monoclonal protection, which kills a broad spectrum of gram-positive & gram-negative bacteria as well as enveloped & non-enveloped viruses, including E.Coli, MRSA, Influenza, Norovirus and SARS-Cov-2. TridAnt is suitable for skin protection as well as most other surfaces including woven and non-woven fabrics including metals (nitinol) as well as polymers (polycarbonate & polyurethanes).”

Experienced NHS GP and specialist in the treatment of microorganism and bacterial infections, Dr Catriona Anderson, stated: “The prospect of a biocompatible technology which can enhance the function of medical devices through eliminating existing microbes and also preventing the formation of new colonies represents a paradigm shift in prevention and treatment of surgical infections. If the results of these lab tests translate into the real world and prolong the active lifecycle of medical devices it will have significant economic, health and social care impact.”